DUBLIN, March 4, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Barclays Global Healthcare Conference in Miami.
The presentation will take place on Tuesday, March 11, 2014 at 9:30 AM Eastern Standard Time at the Lowes Miami Hotel, 1601 Collins Avenue, Miami, FL. To access a live webcast of the presentation, visit...
DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dronedarone Hydrochloride Tablets 400 mg. Actavis' ANDA product is a generic version of Sanofi's Multaq®, which is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persisten...
DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's Colcrys®, which is a prescription medicine used in adults to prevent and treat gout flares.
Takeda Pharmaceuticals U.S.A., Inc. filed suit against Actavis on February 27, 2014 in the U.S. Distri...
- Fourth Quarter 2013 GAAP Loss Per Share of $0.86 -
- 108% Increase in Fourth Quarter 2013 Adjusted EBITDA to $817 million -
- Company affirms 2014 forecast -
DUBLIN, Feb. 20, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today reported net revenue increased 59 percent to $2.779 billion for the fourth quarter ended December 31, 2013, compared to $1.75 billion in the fourth quarter 2012. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2013 increased to $3.17, com...
Lowes Miami Hotel 1601 Collins Avenue Miami, FL US
Morris Corporate Center III
400 Interpace Parkway
Parsippany, NJ 07054
1 Grand Canal Square, Docklands
Dublin 2, Ireland
Stockholder Information Questions concerning stock ownership
may be directed to:
Stock Transfer Agent
PO Box 43001
Providence RI 02940
Toll Free: 855-807-3171
Local: 781-575-4442 www.computershare.com
Independent Accountants PricewaterhouseCoopers LLP
Orange County, California